Trial Profile
Phase I Study of Regorafenib in Patients With Advanced Myeloid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloid leukaemia; Myeloproliferative disorders
- Focus Adverse reactions
- 06 Mar 2024 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 04 Sep 2020 Planned End Date changed from 1 Jan 2023 to 1 Sep 2023.